Records containing: Mesothelioma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2025-07-14A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2025-07-10A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers
-
CLINICAL_TRIALS study record update · 2025-07-09Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2025-06-26Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
-
CLINICAL_TRIALS study record update · 2025-06-25Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-06-05A Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide In Patients With Unresectable Or Metastatic Soft Tissue Sarcoma or Malignant Mesothelioma
-
CLINICAL_TRIALS study record update · 2025-06-05A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma
-
CLINICAL_TRIALS study record update · 2025-05-13Combining a WT1 Cancer Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1-Expressing Malignant Pleural Mesothelioma: A Phase I Study
-
CLINICAL_TRIALS study record update · 2025-05-06Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma
-
CLINICAL_TRIALS study record update · 2025-04-23A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2025-04-10CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma (CONFIRM): A Phase III Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Nivolumab in Relapsed Mesothelioma
-
CLINICAL_TRIALS study record update · 2025-03-21Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff
-
CLINICAL_TRIALS study record update · 2025-03-13A Double-blind, Placebo Controlled, Randomized Multicenter Phase II Study Evaluating Gemcitabine With or Without Ramucirumab as II Line Treatment for Advanced Malignant Pleural Mesothelioma
-
CLINICAL_TRIALS study record update · 2025-01-13Staging Procedures to Diagnose Malignant Pleural Mesothelioma
-
CLINICAL_TRIALS study record update · 2024-12-18The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
-
CLINICAL_TRIALS study record update · 2024-12-17Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response
-
CLINICAL_TRIALS study record update · 2024-12-10A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
-
CLINICAL_TRIALS study record update · 2024-11-25Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
-
CLINICAL_TRIALS study record update · 2024-11-07First in Human Phase 1 Dose Escalation and Expansion Clinical Trial to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of Intravenous AROG4-01 in Patients With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2024-11-01A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
-
CLINICAL_TRIALS study record update · 2024-10-15Developing Optimal Parameters for Hyperpolarized Noble Gas (3He and 129Xe) and Inert Fluorinated Gas Magnetic Resonance Imaging of Lung Disorders
-
CLINICAL_TRIALS study record update · 2024-10-10A Phase 1 Dose Escalation/Dose Finding Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
-
CLINICAL_TRIALS study record update · 2024-10-02A Phase 1/2 Dose Escalation/Expansion Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
-
CLINICAL_TRIALS study record update · 2024-08-26A Phase I, Open-label Multi-dose Two-part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor and a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438) in Subjects With Advanced Malignancies
-
CLINICAL_TRIALS study record update · 2024-08-09A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BGC515 Capsules in Patients With Advanced Solid Tumors